What Are
Exosomes?
A Clinician's Guide

The Basic Biology of Exosomes

Exosomes are small membrane-bound vesicles secreted by virtually every cell type in the body. They range from 30 to 150 nanometers in diameter, placing them in a size category smaller than most viruses and orders of magnitude smaller than a red blood cell. Their defining biological role is intercellular communication: they carry molecular cargo from the cell that produces them and deliver it to recipient cells, where that cargo can alter gene expression, protein production, and cellular behavior.

The term "exosome" refers specifically to vesicles that form inside the cell through a process involving late endosomes, also called multivesicular bodies (MVBs). When an MVB fuses with the plasma membrane, the internal vesicles are released into the extracellular space as exosomes. This distinguishes them from microvesicles, which bud directly from the cell surface, and from apoptotic bodies, which are released during cell death. Together, these three populations constitute the broader category of extracellular vesicles (EVs).

In clinical and commercial contexts, "exosome" is often used as a shorthand for the entire small EV fraction. A 2024 review in Signal Transduction and Targeted Therapy describes exosomes as possessing distinct therapeutic advantages over whole cell therapies, noting their non-immunogenicity, non-infusion toxicity, ease of storage, and absence of tumorigenic potential as key properties driving clinical interest.[1]

What Exosomes Carry and How They Work

The therapeutic interest in exosomes is inseparable from their cargo. Each vesicle contains a complex mixture of bioactive molecules that varies based on the producing cell type and its physiological state. The primary cargo categories are:

When an exosome reaches a target cell, it can interact through several mechanisms: direct membrane fusion, receptor-ligand binding at the cell surface, or endocytosis followed by intracellular cargo release. Each pathway can produce distinct downstream effects depending on the cell type and the specific cargo delivered.

This multi-pathway signaling capacity is a key reason researchers find exosomes scientifically compelling. Rather than delivering a single drug molecule to a single receptor, an exosome simultaneously delivers a complex biological message that can influence multiple cellular processes.

Source Matters: MSCs and Why They Dominate the Research

Not all exosomes are clinically equivalent. The producing cell type determines the cargo composition, and therefore the biological effects the exosomes are likely to have in a recipient tissue. This principle, articulated clearly in a 2025 review in Pharmaceutics, is one of the most clinically important concepts for practitioners evaluating exosome products.[2]

Mesenchymal stem cells (MSCs) have become the dominant source for therapeutic exosome production for several reasons. MSCs are well-characterized, ethically accessible (bone marrow, adipose tissue, umbilical cord Wharton's jelly), scalable in culture, and known to produce exosomes with potent anti-inflammatory and immunomodulatory cargo. A 2024 review in Clinical and Experimental Medicine specifically examined MSC-derived exosomes for tissue repair and inflammatory modulation applications, noting bone marrow, adipose, and umbilical cord sources as the most studied.[3]

As of 2025, MSC-derived EVs account for approximately 61% of interventional EV studies registered on ClinicalTrials.gov. This is not a coincidence. The existing body of MSC biology research provides a mechanistic framework for understanding what their exosomes might do, and a safety track record that supports moving into clinical studies.

The cell source is not a manufacturing detail. It determines the biological identity of the exosome product.

From a procurement standpoint, practitioners evaluating exosome products should always ask: what cell type produced these exosomes, from which tissue, from which donor population, under what culture conditions? These variables meaningfully affect cargo composition and are not interchangeable.

Exosomes vs Whole Stem Cell Therapies

Practitioners coming to exosomes from a stem cell therapy background often ask how these two approaches compare. The distinction matters both clinically and regulatorily.

The 2024 review in Signal Transduction and Targeted Therapy frames exosomes as inheriting the therapeutic effects of their parent cells through the delivery of signaling cargo, while avoiding the risks associated with live cell administration.[1]This framing is useful for practitioners: exosomes are not a replacement for all cell therapy applications, but they offer a distinct profile that is well-suited to outpatient and procedural settings.

The Current State of Clinical Evidence

A 2025 analysis in the Journal of Pharmacology and Pharmacotherapeutics examined 90 registered human clinical trials involving exosomes. The study found a steady increase in trial output from 2020 through 2024, with therapeutic applications accounting for roughly 21% of trials and diagnostic applications making up the majority. MSC-derived exosomes featured prominently in the therapeutic segment.[4]

As of early 2025, there are 292 EV-related clinical trials registered on ClinicalTrials.gov, including 170 interventional studies. The FDA approved its first investigational new drug (IND) application for an EV-based candidate in January 2024. Korea's Ministry of Food and Drug Safety approved a Phase 1b trial for a cord MSC-derived EV product in May 2025. These regulatory milestones indicate that the major oversight agencies are engaging with exosome therapeutics as a legitimate drug class, not as a fringe category.

For practitioners, the honest characterization is that the evidence base is genuine and growing, but the large-scale, placebo-controlled Phase 3 trials that would support broad efficacy claims across most applications do not yet exist. Most clinical work remains at Phase 1 and Phase 2. That makes exosome science a frontier area, not an established therapy with a thick evidentiary dossier.

How to Evaluate an Exosome Product

Quality varies dramatically across the exosome products available to licensed practitioners. Understanding what to look for in a Certificate of Analysis (COA) and what questions to ask a supplier is a core competency for any practice incorporating these biologics.

Regulatory Status in the United States

In the United States, exosome products intended for human use are regulated by the FDA. Depending on manufacturing method, composition, and intended use, they may be classified under Section 351 of the Public Health Service Act as biologics (requiring Biologics License Application), under 21 CFR Part 1271 as human cells, tissues, and cellular and tissue-based products (HCT/Ps) if they meet the criteria for minimal manipulation and homologous use, or as drug products requiring NDA or IND review.

The regulatory landscape for exosomes is actively evolving. The FDA has issued warning letters to companies making unapproved therapeutic claims for exosome products and has signaled increased enforcement attention to this product category. Practitioners should consult current FDA guidance documents and legal counsel when structuring clinical protocols involving exosome-based products. Staying current with FDA communications on this topic is part of responsible clinical practice in this area.

For B2B procurement, the relevant framework centers on sourcing from facilities operating under appropriate regulatory oversight. For injectable preparations, 503B outsourcing facility registration is the current benchmark. See our detailed explainer on 503A vs 503B compounding for more on this distinction.

What Clinicians Should Take Away

Exosomes are a legitimate and scientifically grounded class of biologics with a growing body of peer-reviewed evidence and an active clinical trial landscape. For practitioners considering them in clinical practice, the following principles apply:

Cell source determines cargo, and cargo determines biology. MSC-derived exosomes have the largest and most rigorous evidence base. Quality documentation matters enormously. The regulatory environment is active and evolving. Efficacy claims should track the actual evidence, which is promising but still maturing.

The practitioners best positioned to integrate these biologics responsibly are those who understand the underlying science, ask hard questions of their suppliers, and communicate honestly with patients about where the evidence currently stands.